[ad_1]
-A new version of the vaccine is also being investigated to prepare for the Corona 19 virus variant.
-You have applied for emergency use approval from the UK Medicines and Healthcare Products Regulatory Authority (MHRA) on the 21st
-Inexpensive, can be stored in a normal refrigerator
In a video interview with The Times’ Sunday Times on the 27th (local time), CEO Pascal Sorio (61) said: “I think we have found a formula for success that can benefit from taking the vaccine twice.” . He said: “It is 100% preventable from COVID-19 infection, which is severe enough to require hospitalization.”
CEO Sorio said: “I was surprised when I first discovered this” and “knew for a fact that people might be a little disappointed,” he said.
“Of course, I wish the results were simpler, but because they met the standards set by regulatory authorities around the world, I gave an overall positive assessment,” he added. “I wasn’t expecting a storm to come (stock price drop).
The COVID-19 vaccine developed by AstraZeneca and the University of Oxford showed different immunity effects depending on the dose as a result of an interim analysis of the phase 3 clinical trial. When the full dose of the vaccine was administered twice, the rate of Prevention was only 62.1%, but when the first half dose was administered and the second full dose was administered, the prevention rate increased to 90.0%.
The average prevention rate is 70.4%, which is less effective than the vaccine developed by Pfizer, a US pharmaceutical company, and Bioentech, Germany (95%), and a vaccine developed by the US pharmaceutical company Modena (94, 5%). Because of this, when AstraZeneca and the University of Oxford announced these interim clinical results last month, the share price fell 3.8%.
CEO Sorio said they are also working on a new version of the vaccine with the University of Oxford to prepare for the Corona 19 virus variant.
On the 21st, AstraZeneca and the University of Oxford applied for the emergency use of the Corona 19 vaccine manufactured by both companies to the UK Medicines and Healthcare Products Regulatory Authority (MHRA). MHRA, which conducts non-stop deliberations even during the Christmas holidays, can announce whether the vaccine is approved for emergency use as of the 27th, the Daily Telegraph reported.
Compared to other vaccines, the AstraZeneca-Oxford vaccine is cheaper and can be stored in a general refrigerator, so the transport process is not difficult. The Korean government previously purchased 20 million doses (for 10 million people) of the AstraZeneca vaccine and plans to introduce it in February-March next year.
Copyright © Current Affairs Focus Unauthorized reproduction and redistribution prohibited
